What is the price target for ASLN stock?
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
ASLAN Pharmaceuticals Ltd (ASLN) Forecast, Price Target & Analyst Ratings
NASDAQ:ASLN • US04522R2004
Current stock price
0.6 USD
-0.1 (-14.27%)
At close:
0.56 USD
-0.04 (-6.67%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASLAN Pharmaceuticals Ltd (ASLN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 9, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$3.67
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$77.52
Upside
+ 12,820.00%
From current price of $0.60 to mean target of $77.52, Based on 8 analyst forecasts
Low
$72.72
Median
$77.52
High
$84.00
Price Target Revisions
1 Month
700.00%
3 Months
700.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for ASLN. The average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
The average price target has been revised upward by 700% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
ASLN was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ASLN.
In the previous month the buy percentage consensus was at a similar level.
ASLN was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-05-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-31 | Roth MKM | Initiate | Buy |
| 2023-04-28 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-20 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-27 | Piper Sandler | Maintains | Overweight |
| 2023-02-27 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-16 | Piper Sandler | Maintains | Overweight |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-07-09 | Jefferies | Initiate | Buy |
| 2021-03-17 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 9, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$3.67
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- -3,238.18%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
ASLN is expected to report earnings on 8/9/2024. The consensus EPS estimate for the next earnings is -3.67 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2024 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 3M | -100.00% | 12.24M | -100.00% | 58.856M | 502.56M 753.88% | 1.095B 117.88% | |||||||
| EBITDA YoY % growth | -38.78M | -42.1M -8.56% | -22.07M 47.58% | N/A 26.69% | N/A -107.48% | N/A -41.65% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -38.99M -347.13% | -42.35M -8.62% | -22.51M 46.85% | -14.621M 26.79% | -32.663M -105.40% | -46.832M -41.45% | -42.701M 10.82% | -61.501M -44.03% | -52.02M 15.42% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | -750.33% | N/A | N/A | N/A | -348.87% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -1.38 | -1.43 -3.47% | -1.99 68.32% | -2.43 -146.70% | -3.60 -233.93% | -2.66 -119.25% | -3.41 58.45% | -2.40 29.64% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.67 -3,238.18% | -0.48 14.39% | -1.86 70.25% | -0.56 86.77% | -0.59 83.89% | -0.61 -27.66% | -0.64 65.38% |
| Revenue Q2Q % growth | -100.00% | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.322M -378.86% | -11.577M -11.09% | -27.387M -144.65% | -11.985M -6.86% | -12.75M -12.61% | -13.26M -14.54% | -14.025M 48.79% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
36.90%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ASLAN Pharmaceuticals Ltd / ASLN Forecast FAQ
When does ASLAN Pharmaceuticals Ltd (ASLN) report earnings?
ASLAN Pharmaceuticals Ltd (ASLN) will report earnings on 2024-08-09, before the market open.
Can you provide the consensus estimates for ASLAN Pharmaceuticals Ltd next earnings?
The consensus EPS estimate for the next earnings of ASLAN Pharmaceuticals Ltd (ASLN) is -3.67 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for ASLAN Pharmaceuticals Ltd stock?
The consensus rating for ASLAN Pharmaceuticals Ltd (ASLN) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.